Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
68.00K | 135.00K | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
68.00K | 135.00K | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
-16.02M | -17.84M | -14.21M | -11.61M | -4.45M | -6.45M | EBITDA |
-29.59M | -17.84M | -11.14M | -11.61M | 0.00 | 0.00 | Net Income Common Stockholders |
-30.29M | -24.83M | -26.23M | -23.01M | -4.60M | -3.28M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
503.31K | 1.82M | 176.00K | 47.00K | 510.00K | 2.81M | Total Assets |
106.83M | 4.66M | 3.51M | 4.77M | 603.00K | 2.91M | Total Debt |
0.00 | 574.00K | 9.08M | 8.83M | 2.62M | 83.00K | Net Debt |
-503.31K | -1.25M | 8.90M | 8.78M | 2.11M | -2.72M | Total Liabilities |
10.20M | 6.84M | 17.38M | 13.00M | 76.77M | 74.49M | Stockholders Equity |
96.64M | -2.18M | -13.87M | -8.23M | -76.17M | -71.58M |
Cash Flow | Free Cash Flow | ||||
-15.80M | 0.00 | -10.29M | -7.79M | -5.11M | -5.57M | Operating Cash Flow |
-15.80M | 0.00 | -10.29M | -7.79M | -5.11M | -5.57M | Investing Cash Flow |
0.00 | 0.00 | 0.00 | 0.00 | -105.57M | 0.00 | Financing Cash Flow |
17.81M | 17.65M | 10.41M | 7.33M | 2.82M | 4.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
45 Neutral | $12.78M | 0.91 | -92.54% | ― | -70.05% | ― | |
41 Neutral | $10.21M | ― | -58.40% | ― | ― | 1.00% | |
36 Underperform | $13.39M | ― | 249.03% | ― | 18.54% | 50.37% | |
33 Underperform | $12.35M | ― | 1475.93% | ― | ― | 75.26% | |
32 Underperform | $14.12M | ― | -462.31% | ― | ― | 56.88% |
On January 31, 2025, SeaStar Medical Holdings entered a Securities Purchase Agreement with an institutional investor, issuing shares and warrants in both a registered direct offering and a concurrent private placement, expecting gross proceeds of approximately $6 million. The funds are intended for general corporate purposes, potentially impacting its operational capabilities and market strategy by enhancing working capital and capital expenditures.